52745-93-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
(R)-(-)-4-Methylhexanoic acid is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and properties make it a versatile component in the development of new drugs and agricultural products.
Used in Flavor and Fragrance Industry:
(R)-(-)-4-Methylhexanoic acid is used as a component in the flavor and fragrance industry due to its characteristic earthy and fatty odor. This makes it a valuable addition to the creation of various scents and flavors for consumer products.
Used in Antimicrobial Applications:
(R)-(-)-4-Methylhexanoic acid has been studied for its potential antimicrobial properties. It may be used as an antimicrobial agent in various applications, such as in the development of new antibiotics or as a preservative in the food industry.
Used in Anti-inflammatory Applications:
(R)-(-)-4-Methylhexanoic acid has also been investigated for its potential anti-inflammatory properties. It may be utilized in the development of new anti-inflammatory drugs or as a component in topical creams and ointments for the treatment of inflammation-related conditions.

Upstream product

• 53353-03-0 (R)-(-)-2,6-dimethyl-2-octene 
• 7540-51-4 (S)-3,7-dimethyl-6-octen-1-ol 
• 13722-73-1 4-ethylpent-4-enoic acid 
• 1117-74-4 4-oxohexanoic acid 
• 313653-16-6 methanesulfonic Acid (S)-3,7-dimethyl-oct-6-enyl Ester 

Downstream Products

• 331956-17-3 (R)-4-Methyl-hexanoic acid (1R,2S)-2-[(2-methyl-benzyl)-(2,4,6-trimethyl-benzyl)-amino]-1-phenyl-propyl ester 
• 114088-42-5 (6R,10R,3RS)-2,3-isopropylidenedioxy-2,6,10-trimethyldodecane 
• 70144-70-6 (R,E)-14-methyl-8-hexadecenal 
• 70224-30-5 (R,Z)-14-methylhexadec-8-en-1-one 
• 446262-64-2 (4R)-4-benzyl-3-[(2S,4R)-2,4-dimethylhexanoyl]-1,3-oxazolidin-2-one 
• 221293-02-3 (R)-4-benzyl-3-((R)-4-methylhexanoyl)oxazolidin-2-one 

Relevant academic research and scientific papers

Synthesis of the Entomopathogenic Fungus Metabolites Militarinone C and Fumosorinone A

Militarinone C and fumosorinone A, 3-oligoenoyltetramic acids produced by insect pathogenic fungi, were synthesized for the first time. The pyrrolidine-2,4-dione ring was closed through a late-stage Dieckmann condensation of N-(β-ketoacyl) derivatives of tyrosine, obtained by its acylation with either thioesters or Meldrum's acid derivatives bearing the all-trans-polyene side chain. The latter was built up from (S)-citronellol via an Evans methylation and Wittig or HWE olefinations.

Carboxy-directed asymmetric hydrogenation of 1,1-diarylethenes and 1,1-dialkylethenes

Carboxy marks the spot: A carboxy-directed asymmetric hydrogenation of 1,1-diarylethenes and 1,1-dialkylethenes with chiral iridium/spiro phosphine-oxazoline catalysts has been developed. A wide range of chiral diarylethanes and chiral γ-methyl fatty acids were synthesized with excellent enantioselectivity (see scheme). Copyright

Combinations comprising alpha-2-delta ligands

The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salths thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.

Combinations

The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred ACHE inhibitors are donepezil (Aricept?), tacrine (cognex?), rivastigmine (Exelon?), physostgmine (Synapton?), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil.

METHODS FOR USING AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA PROTEIN

This invention relates to certain ?-amino acids that bind to the alpha-2-delta ((x2S) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

Synergistic combinations

The instant invention relates to a combination of an alpha-2-delta ligand and a PDEV inhibitor for use in therapy, particularly in the curative, prophylactic or palliative treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred PDEV inhibitors are sildenafil, vardenafil and tadalafil.

Alpha2delta ligands for fibromyalgia and other disorders

This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S, 5R)-3-Aminomethyl-5-methyl-octanoic acid

Amino acids with affinity for the alpha-2-delta-protein

This invention relates to certain β-amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

Mono-and disubstituted 3-propyl gamma-aminobutyric acids

The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I 1The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.

Method of treating cartilage damage

The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula 1and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.